Wuhan Healthgen Biotechnology Corp. (SHA:688765)
25.67
-1.60 (-5.87%)
At close: Nov 20, 2026
SHA:688765 Revenue
Wuhan Healthgen Biotechnology had revenue of 9.14M CNY in the quarter ending June 30, 2026, with 43.77% growth. This brings the company's total for the last twelve months to 53.43M, up 88.16% year-over-year. In the year 2025, Wuhan Healthgen Biotechnology had annual revenue of 47.86M with 89.80% growth. That makes Wuhan Healthgen Biotechnology the 38,315th largest company in the world by revenue and 5,134th in China.
Revenue (ttm)
53.43M
Revenue Growth
+88.16%
P/S Ratio
171.77
Revenue / Employee
192.18K
Employees
278
Market Cap
9.18B
Revenue by Geography
- China 41.70M 87.1%
- Overseas 6.16M 12.9%
Fiscal year ended Dec 31, 2025 See the full SHA:688765 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 47.86M | 22.65M | 89.80% |
| Dec 31, 2024 | 25.22M | 952.02K | 3.92% |
| Dec 31, 2023 | 24.26M | 10.86M | 81.08% |
| Dec 31, 2022 | 13.40M | -12.12M | -47.49% |
| Dec 31, 2021 | 25.52M | 3.95M | 18.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.